SCHEMBL2118402

SCHEMBL2118402

Cc1ccc(-c2ccc(C#N)nc2)cc1NS(=O)(=O)c1ccc(O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 2/20 0.44
SLC40A1 Q9NP59 4/20 0.43
PIK3CD O00329 1/20 0.43
PIK3CG P48736 1/20 0.42
POLB P06746 2/20 0.41
RAB9A P51151 1/20 0.41
ACLY P53396 1/20 0.41
AKT1 P31749 1/20 0.41
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP2C9 P11712 2/20 0.41
GAA P10253 2/20 0.41
GFER P55789 1/20 0.41
HSD11B1 P28845 1/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CCR2 P41597 1/20 0.40
MAPT P10636 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120001 0.89 TP53 (0.49) TNFSLC40A1PIK3CDPIK3CGPOLB
SCHEMBL2118686 0.89 PIK3CD (0.47) TNFSLC40A1PIK3CDPIK3CGPOLB
SCHEMBL2118430 0.81 ALDH1A1 (0.44) POLBACLYALDH1A1CYP2C9GAA
SCHEMBL2119080 0.81 ACLY (0.46) POLBACLYALDH1A1CYP2C9GAA
SCHEMBL2120558 0.81 ACLY (0.45) PIK3CGACLYPIK3CAMTORALDH1A1
SCHEMBL2122713 0.81 HSD11B1 (0.47) POLBRAB9AACLYPIK3CAMTOR
SCHEMBL2120131 0.79 ACLY (0.42) POLBACLYALDH1A1CYP2C9GAA
SCHEMBL2120282 0.79 TUBB4A (0.54) ACLYALDH1A1CYP2C9GAAGFER
SCHEMBL2120534 0.78 ABCB1 (0.51) PIK3CDPIK3CGPOLBACLYPIK3CA
SCHEMBL2118662 0.78 ALDH1A1 (0.61) POLBALDH1A1CYP2C9GAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 TNF 135/4885SLC40A1 1338/4885PIK3CD 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.